Spectrum To Test Poziotinib's Potential As First Line Treatment Of Exon 20 Mutant NSCLC

 
• By Jung Won Shin
Neon Light Sign Lungs Icon
Poziotinib trials expanded to first-line EGFR or HER2 Exon 20 mutant NSCLC • Source: Shutterstock

More from Clinical Trials

More from R&D